PBK and acute myeloid leukemia: Interestingly, we demonstrated that the TOPK inhibitor provides potent anti-leukemia activity, even in primary blasts with the FLT3-ITD mutation obtained from patients with AML who progressed after treatment with a potent FLT3 inhibitor (quizartinib, AC220).